Abstract
The blood pressure (BP) waveform varies substantially between the peripheral conduit (brachial) and the central elastic (aorta) arteries mainly do a gradual increase of systolic BP, as the wave propagates distally. This phenomenon is called BP amplification and is principally generated by the presence of arterial stiffness gradient and wave reflections along the arterial bed. More and more clinical studies suggest that central BP may provide additional information regarding cardiovascular risk beyond peripheral BP. Arterial properties and thus pressure amplification, are modulated by age, cardiovascular risk factors, vasoactive substances and drugs. Recent evidence suggests, beyond any doubt, that antihypertensive drugs affect peripheral and central BP differentially and alter pressure amplification. The aim of the present review (Part II) is to summarize the available evidence regarding: (i) the specific class-effect of antihypertensive drugs on central BP beyond peripheral BP, as well as the potential underlying hemodynamic mechanisms, (ii) head to head comparison of the effect of different classes of antihypertensive drugs on central BP, (iii) the effect of combination drug treatment on central BP. Finally to attempt an interpretation of the clinical trials in hypertension, which classically record brachial BP, based on the results of studies which assessed central BP. Several conclusions were drawn. First, it is clear that there are important differences between the classes of antihypertensive drugs regarding their effects on BP amplification. Second, it seems that the newer antihypertensive drugs [angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers and dihydropyridine calcium blockers], as well as nitrates, have a more beneficial effect on BP amplification than the older drugs (diuretics and BBs). Third, there is compelling evidence regarding the detrimental effect of BBs (mainly atenolol) on central BBs and convincing evidence that ACEIs increase BP amplification.
Keywords: Central blood pressure, pressure amplification, arterial stiffness, wave reflections, antihypertensive drugs
Current Pharmaceutical Design
Title: The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification
Volume: 15 Issue: 3
Author(s): Athanase D. Protogerou, George S. Stergiou, Charalambos Vlachopoulos, Jacques Blacher and Apostolos Achimastos
Affiliation:
Keywords: Central blood pressure, pressure amplification, arterial stiffness, wave reflections, antihypertensive drugs
Abstract: The blood pressure (BP) waveform varies substantially between the peripheral conduit (brachial) and the central elastic (aorta) arteries mainly do a gradual increase of systolic BP, as the wave propagates distally. This phenomenon is called BP amplification and is principally generated by the presence of arterial stiffness gradient and wave reflections along the arterial bed. More and more clinical studies suggest that central BP may provide additional information regarding cardiovascular risk beyond peripheral BP. Arterial properties and thus pressure amplification, are modulated by age, cardiovascular risk factors, vasoactive substances and drugs. Recent evidence suggests, beyond any doubt, that antihypertensive drugs affect peripheral and central BP differentially and alter pressure amplification. The aim of the present review (Part II) is to summarize the available evidence regarding: (i) the specific class-effect of antihypertensive drugs on central BP beyond peripheral BP, as well as the potential underlying hemodynamic mechanisms, (ii) head to head comparison of the effect of different classes of antihypertensive drugs on central BP, (iii) the effect of combination drug treatment on central BP. Finally to attempt an interpretation of the clinical trials in hypertension, which classically record brachial BP, based on the results of studies which assessed central BP. Several conclusions were drawn. First, it is clear that there are important differences between the classes of antihypertensive drugs regarding their effects on BP amplification. Second, it seems that the newer antihypertensive drugs [angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers and dihydropyridine calcium blockers], as well as nitrates, have a more beneficial effect on BP amplification than the older drugs (diuretics and BBs). Third, there is compelling evidence regarding the detrimental effect of BBs (mainly atenolol) on central BBs and convincing evidence that ACEIs increase BP amplification.
Export Options
About this article
Cite this article as:
Protogerou D. Athanase, Stergiou S. George, Vlachopoulos Charalambos, Blacher Jacques and Achimastos Apostolos, The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification, Current Pharmaceutical Design 2009; 15 (3) . https://dx.doi.org/10.2174/138161209787354186
DOI https://dx.doi.org/10.2174/138161209787354186 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Vascular Reactions of Iodinated X-Ray Contrast Media: Mechanisms and Possible Therapeutic Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Biological Activity of Cytokines: An Evolutionary Perspective
Current Pharmaceutical Design Salt: A Review of its Role in Food Science and Public Health
Current Nutrition & Food Science The Therapeutic Potential of Differentiated Lung Cells from Embryonic Stem Cells in Lung Diseases
Current Stem Cell Research & Therapy Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Obstetric Anaesthesia and Obesity
Current Women`s Health Reviews Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Insights into the Relationship Between Hypertension and Albuminuria
Current Hypertension Reviews Hypotensive Effect of Hydroalcoholic Ziziphus jujuba Extract on Normotensive Rats
Current Nutrition & Food Science The Effects of Direct Renin Inhibitor, Aliskiren, on Arterial Hypertension, Chronic Kidney Disease and Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pathophysiology of CTGs and Types of Intrapartum Hypoxia
Current Women`s Health Reviews Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design